SCHEMBL25248841

SCHEMBL25248841

Cc1ccc(C(CO)C(=O)O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.50
ALDH1A1 P00352 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GAA P10253 1/20 0.44
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
ACHE P22303 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
LMNA P02545 1/20 0.41
FFAR1 O14842 1/20 0.40
CYP2C19 P33261 1/20 0.40
AKR1C3 P42330 2/20 0.40
AKR1C2 P52895 2/20 0.40
CPN1 P15169 1/20 0.40
CPB2 Q96IY4 1/20 0.40
STAT3 P40763 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL30260177 0.88 SMN1; SMN2 (0.55) POLBSMN1; SMN2ALDH1A1ACHEMEN1
SCHEMBL22035957 0.85 POLB (0.56) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL7705115 0.83 ALDH1A1 (0.56) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL18133693 0.83 ESR1 (0.47) POLBSMN1; SMN2ALDH1A1L3MBTL1ACHE
SCHEMBL510548 0.83 ALDH1A1 (0.56) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL9068550 0.82 POLB (0.57) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL31109105 0.82 POLB (0.61) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL16750534 0.82 ALOX5 (0.46) POLBSMN1; SMN2ALDH1A1L3MBTL1ACHE
SCHEMBL2276811 0.82 L3MBTL1 (0.66) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL27897005 0.82 POLB (0.53) POLBSMN1; SMN2ALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 EP disclosed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 US disclosed
WO-2024245143-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES 赛诺哈勃药业(成都)有限公司 2024-12-05 WO disclosed
EP-4455136-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE Scinnohub Pharmaceutical Co., Ltd. (CN) 2024-10-30 EP disclosed
CN-118510768-A Diazasulfinyl structure-containing compounds and their use in medicine 赛诺哈勃药业(成都)有限公司 2024-08-16 CN disclosed
WO-2023116774-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE 赛诺哈勃药业(成都)有限公司 2023-06-29 WO disclosed
WO-2023116774-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE 赛诺哈勃药业(成都)有限公司 2023-06-29 WO disclosed
CN-110194834-B Visual photoinduced shape memory polymer and preparation method thereof 西南交通大学 2020-07-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L POLB 3832/4885SMN1; SMN2 1443/4885ALDH1A1 2611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.